PTCT Assumes Outperform Rating by Leerink Partners -- Price Target Set at $98

gurufocus.com · 2026-09-14

PTC Therapeutics Receives "Outperform" Rating from Leerink Partners On October 03, 2023, PTC Therapeutics (PTCT) received an "Outperform" rating from Leerink

TickrTrends take: Leerink Partners' outperform rating and price target of $98 for PTCT establishes a specific benchmark against which the company's healthcare operations can be evaluated as TickrTrends completes its full valuation analysis. The analyst perspective from a recognized healthcare research firm provides market-based data that investors focused on valuation metrics should monitor while awaiting the platform's comprehensive assessment. Readers tracking PTCT's valuation should consider how this third-party price target aligns with the company's fundamentals and competitive position in the Healthcare sector as additional information becomes available.

Read the full story at gurufocus.com →